Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASLAN PHARMACEUTICALS LIMITED

(ASLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

09/27/2021 | 06:00am EDT

ASLAN Pharmaceuticals Limited announced positive topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN004, a potential first-in-class monoclonal antibody that targets the IL-13 receptor, was shown to be well tolerated across all doses. Data from the study conclusively establishes proof of concept, and supports the potential of ASLAN004 as a differentiated, novel treatment for AD. ASLAN004 achieved a statistically significant improvement (p


© S&P Capital IQ 2021
All news about ASLAN PHARMACEUTICALS LIMITED
11:12aAsian ADRs Flat in Friday Trading
MT
08:12aASLAN PHARMACEUTICALS : Collaborates With Skin Disease Expert on Study of Potential Atopic..
MT
10/21ASLAN PHARMACEUTICALS : Aslan003
PU
10/21ASLAN PHARMACEUTICALS : Aslan004
PU
10/20Asian ADRs Nudge Higher in Wednesday Trading
MT
10/19Asian ADRs Climb Higher in Tuesday Trading
MT
10/18Asian ADRs Nudge Higher in Monday Trading
MT
10/18ASLAN PHARMACEUTICALS : Announces KOL Event Series to Discuss Atopic Dermatitis Treatment ..
AQ
10/15Asian ADRs Nearly 1% Higher Friday Morning
MT
10/14ASLAN PHARMACEUTICALS : Announces Expansion of Scientific Advisory Board With Appointment ..
AQ
More news
Analyst Recommendations on ASLAN PHARMACEUTICALS LIMITED
More recommendations
Financials
Sales 2021 - - -
Net income 2021 -917 M -32,9 M -32,9 M
Net Debt 2021 - - -
P/E ratio 2021 -3,56x
Yield 2021 -
Capitalization 102 M 102 M 3,68 M
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 18
Free-Float 41,2%
Chart ASLAN PHARMACEUTICALS LIMITED
Duration : Period :
ASLAN Pharmaceuticals Limited Technical Analysis Chart | ASLN | US04522R1014 | MarketScreener
Technical analysis trends ASLAN PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,47 $
Average target price 8,00 $
Spread / Average Target 444%
EPS Revisions
Managers and Directors
Carl Aslan Jason Morton Firth Chief Executive Officer & Director
Kiran Kumar Asarpota Chief Operating Officer & Head-Finance
Andrew James Howden Non-Executive Chairman
Kenneth Kobayashi Chief Medical Officer
Robert E. Hoffman Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ASLAN PHARMACEUTICALS LIMITED-13.11%111
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536